Novartis Ag (NVS) Total Liabilities (2009 - 2026)
Novartis Ag (NVS) posted Total Liabilities of $80.1 billion for Q2 2026, up 24.36% sequentially from $64.4 billion in Q4 2025, and up 28.47% YoY from $62.3 billion in Q2 2025.
Novartis Ag (NVS) Total Liabilities (2009 - 2026) Analysis & Trends
Novartis Ag has reported Total Liabilities for 18 years, with the latest figure at $80.1 billion in Q2 2026.
- Quarterly Total Liabilities rose 28.47% year-over-year to $80.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $80.1 billion (up 28.47% YoY) and the FY2025 annual result came in at $64.4 billion, up 10.81% from the prior year.
- Total Liabilities grew to $80.1 billion in Q2 2026 per NVS's latest filing, from $64.4 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $80.1 billion in Q2 2026 and troughed at $53.2 billion in Q4 2023.
- A 5-year average of $61.2 billion and a median of $59.0 billion in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities decreased 14.28% in 2022, then grew 28.47% in 2026.
- Over 5 years, Total Liabilities stood at $58.0 billion in 2022, then declined by 8.33% to $53.2 billion in 2023, then grew by 9.26% to $58.1 billion in 2024, then advanced by 10.81% to $64.4 billion in 2025, then climbed by 24.36% to $80.1 billion in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $80.1 billion, $64.4 billion, and $62.3 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.09 Bn |
| Dec 31, 2025 | 64.40 Bn |
| Jun 30, 2025 | 62.34 Bn |
| Dec 31, 2024 | 58.12 Bn |
| Jun 30, 2024 | 55.60 Bn |
| Dec 31, 2023 | 53.20 Bn |
| Jun 30, 2023 | 59.05 Bn |
| Dec 31, 2022 | 58.03 Bn |
| Jun 30, 2022 | 59.90 Bn |
| Dec 31, 2021 | 63.97 Bn |
| Jun 30, 2021 | 69.89 Bn |
| Dec 31, 2020 | 71.11 Bn |
| Jun 30, 2020 | 69.88 Bn |
| Dec 31, 2019 | 62.82 Bn |
| Jun 30, 2019 | 64.79 Bn |
| Dec 31, 2018 | 66.87 Bn |
| Jun 30, 2018 | 65.16 Bn |
| Dec 31, 2017 | 58.85 Bn |
| Dec 31, 2016 | 55.23 Bn |
| Dec 31, 2015 | 54.43 Bn |